B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PARP1

MOLECULAR TARGET

poly(ADP-ribose) polymerase 1

UniProt: P09874NCBI Gene: 14216 compounds

PARP1 (poly(ADP-ribose) polymerase 1) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PARP1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Luteolin 5,7,3',4'-tetrahydroxy-flavone,1.102
2Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent0.691
3Bortezomib0.691
4Camptothecin0.691
5Clofarabine0.691
6Daunorubicin0.691
7Demecolcine0.691
8Epirubicin0.691
9Gemcitabine0.691
10Homoharringtonine Semisynthetic derivative of harringtonine that acts as0.691
11Irinotecan0.691
12Nocodazole Nocodazole is0.691
13Podophyllotoxin0.691
14Teniposide0.691
15Thapsigargin0.691
16Trabectedin0.691

About PARP1 as a Drug Target

PARP1 (poly(ADP-ribose) polymerase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented PARP1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PARP1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.